• Product NameCarfilzomib (PR-171)
• Brief DescriptionInhibitors
• Purification99.78%
• Biological ActivityCarfilzomib is an epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.
• Target NameProteasome inhibitor
• CAS No. 868540-17-4
• Calculated MW 719.91
• Formulation C40H57N5O7
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
  Pathways:Proteases/Proteasome; Ubiquitination
  Receptor:Proteasome
  Boling pt:
  Melting pt:
  Solubility:DMSO: 50 mg/mL (69.45 mM)
  Appearance:White Crystalline Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Kortuem KM, Stewart AK. Blood. 2013 Feb 7;121(6):893-7.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting